WVE Wave Life Sciences Ltd
Price (delayed)
$7.57
Market cap
$1.16B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.7
Enterprise value
$885.22M
Wave Life Sciences is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using
Highlights
The quick ratio has soared by 130% YoY and by 51% QoQ
The equity has grown by 48% from the previous quarter
Wave Life Sciences's revenue has surged by 102% QoQ but it has decreased by 4.4% YoY
WVE's gross profit has soared by 102% since the previous quarter but it is down by 4.4% year-on-year
Key stats
What are the main financial stats of WVE
Market
Valuations
Earnings
Shares outstanding
153.49M
Market cap
$1.16B
Enterprise value
$885.22M
Price to earnings (P/E)
N/A
Price to book (P/B)
5.51
Price to sales (P/S)
9.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.17
Revenue
$108.3M
Gross profit
$108.3M
Operating income
-$110.4M
Net income
-$97.01M
EBIT
-$97.01M
EBITDA
-$88.35M
Free cash flow
-$151.96M
Per share
Balance sheet
Liquidity
EPS
-$0.7
EPS diluted
-$0.7
Free cash flow per share
-$1.1
Book value per share
$1.37
Revenue per share
$0.78
TBVPS
$2.55
Total assets
$352.21M
Total liabilities
$134.82M
Debt
$25.4M
Equity
$209.52M
Working capital
$209.44M
Debt to equity
0.12
Current ratio
2.89
Quick ratio
2.74
Net debt/EBITDA
3.13
Margins
Efficiency
Dividend
EBITDA margin
-81.6%
Gross margin
100%
Net margin
-89.6%
Operating margin
-101.9%
Return on assets
-33.6%
Return on equity
-104%
Return on invested capital
N/A
Return on capital employed
-40.2%
Return on sales
-89.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
WVE stock price
How has the Wave Life Sciences stock price performed over time
Intraday
-2.2%
1 week
-24.45%
1 month
-28.38%
1 year
21.12%
YTD
-38.8%
QTD
-6.31%
Financial performance
How have Wave Life Sciences's revenue and profit performed over time
Revenue
$108.3M
Gross profit
$108.3M
Operating income
-$110.4M
Net income
-$97.01M
Gross margin
100%
Net margin
-89.6%
Wave Life Sciences's revenue has surged by 102% QoQ but it has decreased by 4.4% YoY
WVE's gross profit has soared by 102% since the previous quarter but it is down by 4.4% year-on-year
Wave Life Sciences's net margin has shrunk by 76% YoY but it has surged by 66% QoQ
The operating margin has plunged by 70% YoY but it has soared by 64% from the previous quarter
Growth
What is Wave Life Sciences's growth rate over time
Valuation
What is Wave Life Sciences stock price valuation
P/E
N/A
P/B
5.51
P/S
9.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.17
Wave Life Sciences's EPS has increased by 37% from the previous quarter but it has decreased by 30% YoY
The equity has grown by 48% from the previous quarter
Wave Life Sciences's revenue has surged by 102% QoQ but it has decreased by 4.4% YoY
The P/S is 59% below the 5-year quarterly average of 24.2 and 19% below the last 4 quarters average of 12.2
Efficiency
How efficient is Wave Life Sciences business performance
Wave Life Sciences's ROS has plunged by 74% YoY but it has soared by 66% from the previous quarter
Wave Life Sciences's return on equity has surged by 63% QoQ
WVE's return on assets is down by 42% year-on-year but it is up by 36% since the previous quarter
Dividends
What is WVE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for WVE.
Financial health
How did Wave Life Sciences financials performed over time
The total assets is 161% greater than the total liabilities
The quick ratio has soared by 130% YoY and by 51% QoQ
WVE's current ratio has soared by 129% year-on-year and by 52% since the previous quarter
Wave Life Sciences's debt is 88% lower than its equity
Wave Life Sciences's debt to equity has plunged by 85% YoY and by 37% from the previous quarter
The equity has grown by 48% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.